5-141051852-G-T
Variant summary
Our verdict is Likely pathogenic. Variant got 6 ACMG points: 6P and 0B. PM2PP3_Strong
The NM_013340.4(PCDHB1):c.382G>T(p.Asp128Tyr) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000000684 in 1,461,868 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Consequence
NM_013340.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 6 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PCDHB1 | ENST00000306549.6 | c.382G>T | p.Asp128Tyr | missense_variant | Exon 1 of 1 | 6 | NM_013340.4 | ENSP00000307234.4 | ||
PCDHB1-AS1 | ENST00000623741.3 | n.295-682C>A | intron_variant | Intron 3 of 3 | 3 | |||||
PCDHB1-AS1 | ENST00000624139.3 | n.124-682C>A | intron_variant | Intron 1 of 2 | 3 | |||||
PCDHB1-AS1 | ENST00000624778.1 | n.350-682C>A | intron_variant | Intron 2 of 2 | 2 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome AF: 6.84e-7 AC: 1AN: 1461868Hom.: 0 Cov.: 33 AF XY: 0.00000138 AC XY: 1AN XY: 727232
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
not specified Uncertain:1
The c.382G>T (p.D128Y) alteration is located in exon 1 (coding exon 1) of the PCDHB1 gene. This alteration results from a G to T substitution at nucleotide position 382, causing the aspartic acid (D) at amino acid position 128 to be replaced by a tyrosine (Y). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
No publications associated with this variant yet.